Form 4: Organon & Co. CFO Matthew Walsh Reports Stock Transactions
SEC Form 4 Filing
Chief Financial Officer of Organon & Co., Matthew Walsh, reports the vesting and disposal of restricted stock units and common stock transactions on May 4, 2024.
Summary
- On May 4, 2024, Matthew Walsh, the Chief Financial Officer of Organon & Co., reported transactions involving Organon's common stock and restricted stock units (RSUs).
- Walsh disposed of 4,093 shares of common stock at a price of $19.61 per share.
- He also acquired 8,310 shares of common stock upon the vesting of restricted stock units.
- Following these transactions, Walsh beneficially owns 88,326 shares of Organon common stock.
Sentiment
Score: 5
Explanation: This is a neutral report of stock transactions, with no inherent positive or negative sentiment.
Industry Context
This Form 4 filing is a routine disclosure of stock transactions by a company insider, as required by the SEC. It provides transparency to investors regarding the trading activities of company executives.
Stakeholder Impact
- The transactions have a minor impact on shareholders as they reflect insider trading activity, which is a normal part of executive compensation.
Key Dates
| Date | Description |
|---|---|
| 05/04/2022 | One-third of the RSUs vested. |
| 05/04/2023 | One-third of the RSUs vested. |
| 05/04/2024 | Date of the reported transactions: vesting of RSUs and disposal of common stock; one-third of the RSUs vested. |
| 05/07/2024 | Date of signature for the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.